Treg: A Promising Immunotherapeutic Target in Oral Diseases

被引:29
|
作者
Zhang, Yujing [1 ]
Guo, Jihua [1 ,2 ]
Jia, Rong [1 ]
机构
[1] Wuhan Univ, Sch & Hosp Stomatol, Key Lab Oral Biomed, State Key Lab Breeding Base Basic Sci Stomatol,Mi, Wuhan, Peoples R China
[2] Wuhan Univ, Sch & Hosp Stomatol, Dept Endodont, Wuhan, Peoples R China
来源
FRONTIERS IN IMMUNOLOGY | 2021年 / 12卷
关键词
Treg; immunotherapy; oral diseases; periodontitis; oral cancer; REGULATORY T-CELLS; TRANSCRIPTION FACTOR FOXP3; PERIODONTAL-DISEASE; CUTTING EDGE; DENDRITIC CELLS; GRANZYME-B; DIFFERENTIAL EXPRESSION; MEDIATED SUPPRESSION; KAPPA-B; HEAD;
D O I
10.3389/fimmu.2021.667862
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
With the pandemic of COVID-19, maintenance of oral health has increasingly become the main challenge of global health. Various common oral diseases, such as periodontitis and oral cancer, are closely associated with immune disorders in the oral mucosa. Regulatory T cells (Treg) are essential for maintaining self-tolerance and immunosuppression. During the process of periodontitis and apical periodontitis, two typical chronic immune-inflammatory diseases, Treg contributes to maintain host immune homeostasis and minimize tissue damage. In contrast, in the development of oral precancerous lesions and oral cancer, Treg is expected to be depleted or down-regulated to enhance the anti-tumor immune response. Therefore, a deeper understanding of the distribution, function, and regulatory mechanisms of Treg cells may provide a prospect for the immunotherapy of oral diseases. In this review, we summarize the distribution and multiple roles of Treg in different oral diseases and discuss the possible mechanisms involved in Treg cell regulation, hope to provide a reference for future Treg-targeted immunotherapy in the treatment of oral diseases.
引用
收藏
页数:15
相关论文
共 50 条
  • [1] Mycobacterium w - a promising immunotherapeutic intervention for diseases
    Stefan, Kirsten
    Gordon, Ryan
    Rolig, Annah
    Honkala, Alexander
    Tailor, Dhanir
    Davis, Lara E.
    Modi, Rajiv I.
    Joshipura, Manjul
    Khamar, Bakulesh
    Malhotra, Sanjay V.
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [2] T Lymphocytes: A Promising Immunotherapeutic Target for Pancreatitis and Pancreatic Cancer?
    Zhou, Qi
    Tao, Xufeng
    Xia, Shilin
    Guo, Fangyue
    Pan, Chen
    Xiang, Hong
    Shang, Dong
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [3] SLAMF7 as a Promising Immunotherapeutic Target in Multiple Myeloma Treatments
    Chu, Emily
    Wu, Jian
    Kang, Stacey S.
    Kang, Yubin
    CURRENT ONCOLOGY, 2023, 30 (09) : 7891 - 7903
  • [4] Tumor-associated macrophages: A promising target for a cancer immunotherapeutic strategy
    Zhang, Si-Yu
    Song, Xin-Yu
    Li, Yang
    Ye, Lin-Lin
    Zhou, Qiong
    Yang, Wei-Bing
    PHARMACOLOGICAL RESEARCH, 2020, 161
  • [5] LILRB4 as a novel immunotherapeutic target for multiple diseases
    Wang, Xu
    Li, Lanying
    Liu, Dan
    Jin, Yuhang
    Zhao, Xuan
    Li, Sijin
    Hou, Rui
    Guan, Zhangchun
    Ma, Wen
    Zheng, Junnian
    Lv, Ming
    Shi, Ming
    BIOCHEMICAL PHARMACOLOGY, 2025, 233
  • [6] Current antifungal drugs and immunotherapeutic approaches as promising strategies to treatment of fungal diseases
    Nami, Sanam
    Aghebati-Maleki, Ali
    Morovati, Hamid
    Aghebati-Maleki, Leili
    BIOMEDICINE & PHARMACOTHERAPY, 2019, 110 : 857 - 868
  • [7] Pyroptosis: A promising therapeutic target for noninfectious diseases
    Li, Tong
    Zheng, Guangjuan
    Li, Ben
    Tang, Lipeng
    CELL PROLIFERATION, 2021, 54 (11)
  • [8] TIGIT as a Promising Therapeutic Target in Autoimmune Diseases
    Yue, Chenran
    Gao, Sheng
    Li, Shuting
    Xing, Zhouhang
    Qian, Hengrong
    Hu, Ying
    Wang, Wenqian
    Hua, Chunyan
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [9] Saliva – A Promising Tool for Diagnosing Oral Diseases
    Wu D.T.
    Tao O.
    Trinh N.
    Javaid M.A.
    Ahmed A.S.
    Durand R.
    Tran S.D.
    Current Oral Health Reports, 2018, 5 (4) : 242 - 249
  • [10] Promising cancer immunotherapeutic agent
    Li, B.
    VanRoey, M.
    Triebel, F.
    Jooss, K.
    EXPERT REVIEW OF VACCINES, 2008, 7 (06) : 710 - 710